Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.
Lillian
L
Sung
Richard
R
Aplenc
Todd A
TA
Alonzo
Robert B
RB
Gerbing
Alan S
AS
Gamis
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D007964:Leukocytosis / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D008297:Male; D015996:Survival Rate
D003561:Cytarabine; D005047:Etoposide; D003630:Daunorubicin